Bobak R. Azamian - Jan 9, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
President/CEO and Board Chair, Director
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Jan 9, 2023
Transactions value $
-$24,773
Form type
4
Date filed
1/11/2023, 07:26 PM
Previous filing
Jan 24, 2023
Next filing
Jan 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale -$11K -729 -0.06% $15.15 1.13M Jan 9, 2023 By the Bobak Azamian Living Trust established April 16, 2018 F1, F2, F3
transaction TARS Common Stock Sale -$13.7K -905 -0.08% $15.17 1.13M Jan 10, 2023 By the Bobak Azamian Living Trust established April 16, 2018 F1, F3, F4
holding TARS Common Stock 1.75K Jan 9, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
F2 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.02 to $15.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F4 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.00 to $15.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.